NARCOLEPSY TYPE 2
Clinical trials for NARCOLEPSY TYPE 2 explained in plain language.
Never miss a new study
Get alerted when new NARCOLEPSY TYPE 2 trials appear
Sign up with your email to follow new studies for NARCOLEPSY TYPE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Extended trial tests new sleep disorder medication
Disease control Recruiting nowThis study continues testing ALKS 2680 tablets for people with narcolepsy or idiopathic hypersomnia who completed earlier trials. Researchers want to see how safe the medication is over a longer period and whether its benefits last. Participants will take the tablets regularly to…
Matched conditions: NARCOLEPSY TYPE 2
Phase: PHASE2, PHASE3 • Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Extended trial tests sleep disorder Drug's Long-Term safety
Disease control Recruiting nowThis study continues testing the safety and effectiveness of ORX750 medication for people with narcolepsy or idiopathic hypersomnia who completed an earlier trial. It follows 90 participants to monitor long-term side effects and whether the drug continues to help with daytime sle…
Matched conditions: NARCOLEPSY TYPE 2
Phase: PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New brain protein mimic aims to wake up sleep disorder patients
Disease control Recruiting nowThis study is testing a new drug called ORX750 in people with narcolepsy or idiopathic hypersomnia, conditions that cause severe daytime sleepiness. The main goals are to see if the drug is safe and how the body processes it. Researchers also want to find out if it can help peopl…
Matched conditions: NARCOLEPSY TYPE 2
Phase: PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New brain chemical mimic could help people stay awake
Disease control Recruiting nowThis study is testing an experimental medication called TAK-360 for adults with narcolepsy type 2, a condition that causes severe daytime sleepiness. Researchers want to find a safe and effective dose that helps people stay awake and alert. About 88 participants will be randomly …
Matched conditions: NARCOLEPSY TYPE 2
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Spain launches major count of rare sleep disorder
Knowledge-focused Recruiting nowThis study aims to find out exactly how many people in Spain have narcolepsy, a rare sleep disorder causing severe daytime sleepiness. Researchers will review hospital records across the country to count diagnosed cases and track how many new cases appear each year. The goal is t…
Matched conditions: NARCOLEPSY TYPE 2
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:17 UTC